A study in humans demonstrated that the miR-1229-3p was selected from RNA-seq for validation as a potential biomarker for plaque rupture or plaque erosion in patients with ST-segment elevation myocardial infarction, based on criteria of an area under the curve greater than 0.6 or involvement in the underlying pathological mechanism [Li et al. DOI:10.1016/j.ygeno.2020.11.019].